Here’s what you should know:
1. Dr. Alistar has been at the forefront of CPI-613 research. She conducted early stage clinical trials of the treatment and will serve as co-principal investigator on a phase-III combination therapy study of CPI-613 and modified Folfirinox.
2. In addition to this upcoming study, Dr. Alistar led four other clinical trials for CPI-613, as well as several for oncology drugs.
3. She said, “Pancreatic cancer has a very low survival rate. This is due in part to the fact that it is often discovered in a late stage. Early detection can make a difference.”
More articles on gastroenterology:
Tufts Medical Center, Texas Gastroenterology Institute & more: 6 GI practices in the news
FDA approves Synergy Pharmaceuticals’ Trulance for adults with IBS-C — 3 insights
AGA launches patient app aimed at IBD monitoring, education — 3 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.